Last reviewed 2026-05-19 · How we verify

Part A: Lu AF35700

H. Lundbeck A/S · Phase 1 active Small molecule ✓ Verified May 2026

Part A: Lu AF35700 is a Small molecule drug developed by H. Lundbeck A/S. It is currently in Phase 1 development.

Lu AF35700 is a somatostatin receptor binding agent, classified as a binding agent. It was studied in a clinical trial (NCT02093169) involving healthy men to assess its effects after oral dosing.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Part A: Lu AF35700
Sponsor	H. Lundbeck A/S
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Part A: Lu AF35700 CI brief — competitive landscape report
Part A: Lu AF35700 updates RSS · CI watch RSS
H. Lundbeck A/S portfolio CI

Frequently asked questions about Part A: Lu AF35700

What is Part A: Lu AF35700?

Part A: Lu AF35700 is a Small molecule drug developed by H. Lundbeck A/S.

Who makes Part A: Lu AF35700?

Part A: Lu AF35700 is developed by H. Lundbeck A/S (see full H. Lundbeck A/S pipeline at /company/h-lundbeck-a-s).

What development phase is Part A: Lu AF35700 in?

Part A: Lu AF35700 is in Phase 1.

Manufacturer: H. Lundbeck A/S — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing